Inflammation-based Glasgow prognostic score as an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma

0
0
0

Inflammation-based Glasgow prognostic score as an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive blood cancer that targets the immune system’s T-cells, often causing swollen lymph nodes, unexplained fevers, night sweats, rapid weight loss, or autoimmune complications like hemolysis. It’s a tough disease to treat—current tools for predicting survival, such as the Peripheral T-Cell Lymphoma Prognostic Index (PIT), have limits. But a new study from Chinese researchers suggests a simple, inflammation-based score could help doctors better guide care for AITL patients.

The Glasgow Prognostic Score (GPS): A Simple Tool for Complex Cancer

The Glasgow Prognostic Score (GPS) uses two common blood tests to assess risk:

  • C-reactive protein (CRP): Rises when the body is inflamed (a hallmark of cancer growth).
  • Albumin: Drops during illness or malnutrition, signaling the body’s ability to fight disease.

GPS scores range from 0 (low risk) to 2 (high risk):

  • GPS 0: Normal CRP (35 g/L)
  • GPS 1: Either high CRP or low albumin
  • GPS 2: Both high CRP and low albumin

While GPS is widely used for solid tumors (e.g., kidney, liver, or colorectal cancer), no one had tested it in AITL—until researchers from Sun Yat-sen University Cancer Center and The First Affiliated Hospital of Hainan Medical University decided to investigate.

What the Study Found

The team analyzed data from 106 AITL patients diagnosed between 2009 and 2019, tracking factors like age, symptoms, blood work (LDH, hemoglobin, platelets), cancer stage, bone marrow involvement, and treatment response (to CHOP, EPOCH, or GEMOX regimens). The goal? See if GPS could predict two key outcomes: overall survival (how long patients lived) and progression-free survival (time without cancer growth or relapse).

The results were striking:

  1. GPS predicts survival better than PIT:
    • Patients with GPS 0 (28% of the group) had a 76% 5-year survival rate—far higher than GPS 1 (43%) or GPS 2 (0%).
    • Even among “low-risk” PIT patients, GPS split outcomes further: GPS 0 patients had an 88% 5-year survival rate, while GPS 1/2 patients fared much worse.
  2. GPS works for common treatments:
    • For patients on the CHOP regimen (the most widely used therapy), GPS was more reliable than PIT. GPS 0 patients had a 73% complete response rate—double the rate for GPS 2 patients (41%).
  3. GPS is independent of other factors:
    • After adjusting for age, elevated LDH (a cancer marker), anemia, or PIT score, GPS remained the strongest predictor of survival. Patients with GPS 2 were 5.7 times more likely to die and 3.3 times more likely to have cancer progress than those with GPS 0.

Why GPS Matters for AITL

Inflammation drives cancer growth, and GPS captures two critical signals:

  • High CRP: Indicates the body is flooded with pro-tumor inflammatory molecules.
  • Low albumin: Suggests malnutrition or a weakened immune system, making it harder to tolerate treatment.

Together, these markers paint a clearer picture of how well a patient’s body is fighting the lymphoma—something PIT (which relies on age, LDH, performance status, and stage) doesn’t fully capture.

What This Means for Patients

AITL is challenging to treat, but GPS offers a cheap, accessible way to personalize care:

  • GPS 0: Standard chemo (e.g., CHOP) may work well.
  • GPS 1/2: Aggressive therapy or clinical trials could be a better fit.

Best of all, GPS uses routine blood tests—no extra scans or costs.

The Takeaway

This study adds GPS to the toolbox for AITL care. It’s simple, reliable, and better at predicting survival than existing scores for low-risk patients. While more research is needed to understand why GPS works so well, it’s a promising step toward helping doctors make faster, more informed decisions for AITL patients.

The study was led by Guan-Jun Chen and Zhi-Jun Wuxiao (co-first authors) and Hua Wang (corresponding author) from the Department of Hematological Oncology at Sun Yat-sen University Cancer Center and The First Affiliated Hospital of Hainan Medical University. It was published in the Chinese Medical Journal in 2021.

doi.org/10.1097/CM9.0000000000001345

Was this helpful?

0 / 0